HAIFA, Israel, Dec. 22, 2025 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) ("ZIM" or the "Company") today provided an investor update on its strategic review process. As part of the review of strategic alternatives that has been on-going during the past several months, the ZIM Board of Directors received competitive proposals from multiple strategic parties to acquire all the outstanding ordinary shares of the Company, and it is currently evaluating such proposals with a focus on delive ...

Mediterranean Shipping Company (MSC) is denying reports that it is a suitor for fellow container shipping line ZIM, scratching off one possible option for the ocean carrier. “We wish to deny any interest in acquiring ZIM,” an MSC spokesperson told maritime shipping publication Lloyd’s List on Wednesday, saying a bid was never on the table. More from Sourcing Journal Sourcing Journal reached out to MSC. Israeli business publication Calcalist first reported that the Switzerland-based company, which operat ...

Core Viewpoint - Corvex Management LP has accumulated a 6.05% stake in Whitbread PLC and is calling for a strategic review of the company's direction and capital allocation to maximize shareholder value [1][2]. Investment Rationale - Corvex believes that Whitbread's current market price does not reflect its fundamental value, particularly undervaluing its UK freehold hotel portfolio and other significant business components such as the UK leasehold portfolio, German hotel assets, and development properties [2][3]. Strategic Review Proposal - Corvex suggests that Whitbread should conduct a strategic review to reassess its capital allocation priorities and overall strategic direction, ideally with the assistance of an independent financial adviser to ensure an unbiased evaluation of options [3]. - The review should include an assessment of the company's current five-year capital plan, which involves approximately £3.5 billion in investments, nearly equivalent to the company's market capitalization [3]. Board Engagement - Corvex intends to seek representation on Whitbread's Board and aims to collaborate constructively with the company's directors and management to facilitate the strategic review [4].

This story was originally published on Multifamily Dive. To receive daily news and insights, subscribe to our free daily Multifamily Dive newsletter. Dive Brief: Like some of its larger peers, small REIT MacKenzie Realty Capital has initiated a strategic review of its multifamily portfolio to enhance shareholder value, according to a Dec. 12 news release. “We believe the net asset value of our multifamily portfolio alone greatly exceeds our market capitalization,” Robert Dixon, CEO and president of MacKe ...

HAIFA, Israel, Dec. 16, 2025 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) ("ZIM" or the "Company") today announced that it has reached an agreement with a shareholder group led by Mor Gemel Pension Ltd., Reading Capital Ltd. and Sparta 24 Ltd. (the "Shareholder Group") regarding the composition of the Company's Board of Directors ahead of ZIM's upcoming Annual and Extraordinary General Meeting of Shareholders scheduled to be held on December 26, 2025 (the "Annual Meeting"). Pursuant to ...

Core Viewpoint - MacKenzie Realty Capital, Inc. has initiated a strategic review of its multi-family portfolio to enhance shareholder value, believing that the net asset value of this portfolio significantly exceeds its current market capitalization [1][2]. Company Overview - MacKenzie Realty Capital, Inc. is a West Coast-focused Real Estate Investment Trust (REIT) founded in 2013, aiming to invest at least 80% of its total assets in real property and up to 20% in illiquid real estate securities [2]. - The company's real property portfolio is intended to be approximately 50% multifamily and 50% boutique class A office, currently comprising interests in 5 multifamily properties, 8 office properties, and 1 multifamily development [2].

Core Viewpoint - NN, Inc. has formed a Strategic Committee to explore various strategic and financial alternatives aimed at enhancing shareholder value [1][2][3] Group 1: Strategic Committee Formation - The Strategic Committee consists of three independent directors: Raynard Benvenuti, Jeri Harman, and Thomas Wilson [2] - The committee's role is to evaluate a wide range of strategic, financial, and business configuration options for the company [2] Group 2: Company Achievements and Future Focus - The Board's decision reflects a commitment to maximizing shareholder value, with recent accomplishments including strengthening the executive team, expanding operating income and EBITDA, and building a new sales pipeline exceeding $800 million [3] - The company has secured approximately $200 million in new business, entered medical and data center markets, and developed a healthy M&A pipeline [3] - NN is positioned for growth and aims to advance its transformation plan while delivering high-quality products and services [3] Group 3: Advisory Engagement - NN has engaged Houlihan Lokey as its financial advisor to assist in the strategic review process [2] - There is no set timetable for the completion of the review, and the company will provide updates only upon the Board's approval of specific actions [3]

Core Viewpoint - ZIM is facing a proxy fight initiated by an investor group that controls over 5% of its stock, while the company is undergoing a strategic review that may include a sale [1][4]. Group 1: Proxy Fight and Board Dynamics - An investor group led by Mor Gemel & Pension Ltd., Reading Capital Ltd., and Sparta 24 Ltd. has nominated three directors to ZIM's board [1]. - ZIM disclosed the proxy fight in a letter to shareholders, raising concerns about the investor group's transparency due to a lack of required disclosures [2]. - Institutional Shareholder Services (ISS) supports ZIM's board, recommending shareholders vote for all eight current directors and against the three nominated by the investor group [2]. Group 2: Strategic Review and Acquisition Interest - ZIM's board confirmed a strategic review process, which may involve a sale, and has received multiple indications of interest from potential bidders [4]. - Reports indicate that ZIM has received at least three acquisition offers, including one from Hapag-Lloyd [4]. - The board has engaged independent financial and legal advisors to assist in the review process and has formed a transaction committee [5]. Group 3: Management and Shareholder Relations - The board unanimously determined that a takeover bid from CEO Eli Glickman and shipping tycoon Abraham Ungar materially undervalued the company [5]. - The board criticized the dissident group for not engaging meaningfully on the issues raised and for submitting nominations without prior discussion [6]. - The board's letter suggests that the dissident group's campaign is based on misleading assumptions regarding the strategic review process [5][6].

Core Viewpoint - ZIM Integrated Shipping Services Ltd. has demonstrated strong operational and financial performance, emphasizing its commitment to shareholder value and ongoing strategic review amid a proxy fight with dissident shareholders [1][2][3]. Company Performance - Since its IPO in 2021, ZIM has achieved total shareholder returns exceeding 300%, outperforming larger global carriers and the S&P 500 [4]. - The company has grown its fleet from approximately 70 to 129 vessels, doubling its TEU carrying capacity, and maintained EBIT margins averaging 30% since the IPO [6]. - ZIM has returned $5.7 billion in dividends since its IPO, equating to over $47 per share, which is more than three times the IPO price [6]. Strategic Review - The Board is conducting a comprehensive strategic review to assess opportunities for enhancing shareholder value, prompted by an unsolicited proposal from the CEO that was deemed to undervalue the company [9][10]. - The review is ongoing and includes evaluating potential alternatives and enhancements to ZIM's standalone plan, with multiple indications of interest received [11]. Board Composition - ZIM's Board is independent and has been significantly refreshed, with five of eight directors added since the IPO, bringing substantial expertise in finance, M&A, and operational leadership [12]. - The independent Board meets weekly to oversee the strategic review process, ensuring active engagement and oversight [12]. Response to Dissident Group - The dissident group's campaign is criticized for being based on misleading assumptions and lacking constructive engagement with the Board [13][15]. - The dissident nominees are noted to have limited relevant experience in shipping and logistics, which raises concerns about their ability to oversee ZIM's strategic review [19][20]. - The Board emphasizes the importance of maintaining independent oversight to protect shareholder value and ensure a successful strategic review [23][24].

Core Viewpoint - Neuphoria Therapeutics Inc. is urging shareholders to vote for its director nominees on the WHITE proxy card, following a recommendation from Institutional Shareholders Services (ISS) that supports the company's management against a proxy contest initiated by Lynx1 Capital Management [1][2][3] Group 1: Company Overview - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders [7] - The company is advancing its lead drug candidate, BNC210, which is designed to treat post-traumatic stress disorder (PTSD) and is characterized as a first-of-its-kind anti-anxiety therapeutic [7] - Following the Phase 3 clinical trial results announced on October 20, 2025, which missed primary and secondary endpoints, Neuphoria has halted development of BNC210 for social anxiety disorder and is conducting a strategic review [7] Group 2: Proxy Contest and ISS Recommendation - ISS has recommended that Neuphoria shareholders vote FOR both of the company's director nominees, Peter Miles Davies and David Wilson, and WITHHOLD votes for the dissident nominees from Lynx1 Capital Management [2][3] - The ISS report highlighted that the dissident has not presented a compelling case for change, thus supporting the management's nominees [3] - Neuphoria's board has been proactive in raising capital ahead of the Phase 3 trial data readout, strengthening the company's balance sheet as it proceeds with a strategic review [6]